Keyword Analysis & Research: hookipa


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
hookipa0.210.42427147

Keyword Research: People who searched hookipa also searched

Keyword CPC PCC Volume Score
hookipa1.50.8979157

Search Results related to hookipa on Search Engine

  • Hookipa Pharma - Supercharging Immunotherapy

    hookipapharma.com

    https://www.hookipapharma.com/

    WEBJan 29, 2024 · Hookipa Pharma Inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind, we created unique and cutting-edge technologies to reprogram and stimulate the immune system.

    DA: 23 PA: 49 MOZ Rank: 48

  • HOOKIPA Pharma Announces FDA Clearance of its Investigational …

    yahoo.com

    https://finance.yahoo.com/news/hookipa-pharma-announces-fda-clearance-110100277.html

    WEB1 day ago · HOOKIPA’s HB-700 program is designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers by targeting the five most prevalent KRAS mutations in these disease indications: G12D ...

    DA: 39 PA: 29 MOZ Rank: 17

  • HOOKIPA Pharma Announces FDA Clearance of its - GlobeNewswire

    globenewswire.com

    https://www.globenewswire.com/news-release/2024/04/24/2868480/0/en/HOOKIPA-Pharma-Announces-FDA-Clearance-of-its-Investigational-New-Drug-Application-for-HB-700-for-the-Treatment-of-KRAS-Mutated-Cancers.html

    WEB1 day ago · HOOKIPA explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward ...

    DA: 90 PA: 6 MOZ Rank: 57

  • HOOKIPA Pharma Announces FDA Clearance of its Investigational …

    hookipapharma.com

    https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-announces-fda-clearance-its-investigational-new

    WEBNov 20, 2023 · NEW YORK and VIENNA, Austria, Nov. 20, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its …

    DA: 83 PA: 87 MOZ Rank: 50

  • HOOKIPA Pharma Announces FDA Clearance of its Investigational …

    yahoo.com

    https://finance.yahoo.com/news/hookipa-pharma-announces-fda-clearance-120100951.html

    WEBNov 20, 2023 · NEW YORK and VIENNA, Austria, Nov. 20, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...

    DA: 67 PA: 30 MOZ Rank: 7


  • HOOKIPA announces strategic collaboration and license …

    hookipapharma.com

    https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-announces-strategic-collaboration-and-license-agreement

    WEBNEW YORK and VIENNA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced today a strategic collaboration and license agreement with Roche to develop HB-700 for KRAS-mutated cancers and a second …

    DA: 18 PA: 77 MOZ Rank: 44

  • Pipeline - Hookipa Pharma

    hookipapharma.com

    https://www.hookipapharma.com/our-programs/our-pipeline/

    WEBOur ambition is prevention and cure. Our universal technology can be used in prophylaxis or therapy. It is based on a patent-protected family of engineered viruses, which naturally elicit neutralizing antibodies and extremely potent T cell responses. The efficacy of our TheraT® and Vaxwave® platforms are being tested all across our pipeline.

    DA: 53 PA: 15 MOZ Rank: 22

  • HOOKIPA Pharma Inc. (HOOK) Stock Price, News, Quote

    yahoo.com

    https://finance.yahoo.com/quote/HOOK/

    WEBHOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's...

    DA: 46 PA: 5 MOZ Rank: 13

  • HOOKIPA Announces First Patient Enrolled in Phase 2 Trial

    globenewswire.com

    https://www.globenewswire.com/news-release/2022/01/18/2368288/0/en/HOOKIPA-Announces-First-Patient-Enrolled-in-Phase-2-Trial-Evaluating-HB-200-and-Pembrolizumab-for-Treatment-of-Head-and-Neck-Cancer-and-Reports-FDA-s-Fast-Track-Designation.html

    WEBJan 18, 2022 · NEW YORK and VIENNA, Austria, Jan. 18, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...

    DA: 65 PA: 17 MOZ Rank: 51

  • Company Overview - Hookipa Pharma

    hookipapharma.com

    https://www.hookipapharma.com/our-company/about-us/

    WEBHOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to fight cancer and chronic infectious disease. We are pioneering a proprietary arenavirus platform technology to develop therapies that are designed to reprogram the body’s immune system.

    DA: 46 PA: 38 MOZ Rank: 1